Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly